Rs 1000 crore pharma doctor nexus: SC takes cognizance, to decide on making UCPMP mandatory

Published On 2022-08-20 12:30 GMT   |   Update On 2022-08-20 12:30 GMT

The messy issue of pharma companies bribing doctors with various freebies, once again reached the corridors of the Supreme Court yesterday, when during the hearing of the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) matter, allusion was made to the recent IT raid on makers of Dolo 650, and incriminating records that allegedly revealed a payment of Rs 1000 crore freebies to doctors by Micro Labs.

The Supreme Court Thursday was told by an NGO, that has filed a plea demanding to make UCPMP mandatory, that the Central Board of Direct taxes has accused the Pharma company manufacturing popular Dolo tablets, an anti-inflammatory, fever reducer drug, of distributing Rs 1000 crore freebies to doctors for prescribing a dosage of its 650 mg tablets.
For more details click on the link given below :


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News